

Serial No.: 09/472,662
Filing Date: December 27, 1999

A1 fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoetins 1 and 2, bone morphogenetic proteins, nerve growth factor, and growth hormone.

A2 6. (Amended) The method of claim 5 wherein said growth factor is selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor, fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoetins 1 and 2, bone morphogenetic proteins, nerve growth factor, and growth hormone.

11. (Amended) A growth factor composition for enhancing the growth and development of embryonic metanephric tissue comprising two or more growth factors for metanephric development.

A3 12. (Amended) The growth factor composition of claim 11 wherein said two or more growth factors are selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor, fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoetins 1 and 2, bone morphogenetic proteins, nerve growth factor, and growth hormone.

{ Please add the following new claims: }

13. (New) The embryonic metanephric tissue of claim 3 wherein said growth factor composition comprises vitamin A.

A4 14. (New) The method of claim 5 wherein said growth factor composition comprises vitamin A.

15. (New) The growth factor composition of claim 11 wherein said growth factor composition comprises vitamin A.

REMARKS

Claims 3-15 are pending. An Appendix of Pending Claims is attached for the Examiner's convenience.